Pathophysiology of Low C3 and Alternative Pathway Dysregulation in Glomerulonephritis
Low serum C3 with abnormal alternative pathway activity reflects uncontrolled activation of the alternative complement pathway in the kidney, leading to continuous C3 cleavage and deposition of C3 fragments in glomerular structures, which directly damages the filtration barrier and triggers inflammatory injury. 1
Mechanism of Alternative Pathway Activation
The alternative pathway operates through a continuous low-level "tick-over" mechanism that becomes pathologic when regulatory proteins fail:
C3 convertase (C3bBb) stabilization occurs when regulatory proteins (Factor H, Factor I, CD46) are deficient or dysfunctional, allowing the convertase to remain active and continuously cleave C3 into C3a and C3b. 2
Amplification loop acceleration results from genetic mutations in complement regulatory genes (C3, CFH, CFI, CFB, CD46, CFHR1-5) or acquired autoantibodies (C3 nephritic factor, anti-Factor H antibodies) that prevent normal pathway downregulation. 3, 2
Properdin deficiency or dysfunction can paradoxically lead to alternative pathway dysregulation, as properdin normally stabilizes the C3 convertase; abnormalities in properdin levels precede clinical nephritis onset. 4, 5
Glomerular Injury Cascade
Once alternative pathway dysregulation occurs, a specific sequence of renal damage unfolds:
C3 fragment deposition accumulates in the glomerular basement membrane, mesangium, and subendothelial spaces at levels ≥100-fold greater than any immunoglobulin, creating the pathognomonic immunofluorescence pattern of C3 glomerulopathy. 1, 3
Terminal complement activation proceeds when C5 is cleaved into C5a (a potent inflammatory mediator) and C5b, which initiates assembly of the membrane attack complex (C5b-9); patients with C3 glomerulonephritis show significantly elevated soluble C5b-9 and C5a levels compared to controls. 6
Direct podocyte and endothelial injury occurs through membrane attack complex insertion into cell membranes, causing cell lysis and proteinuria; laser dissection mass spectrometry of affected glomeruli demonstrates accumulation of alternative pathway proteins (C3, Factor B, properdin) and terminal complement complex components (C5b-9). 2, 6
Serum Biomarker Profile
The systemic complement profile reflects ongoing glomerular consumption and activation:
Serum C3 depression results from continuous consumption in the kidney; C3 levels are significantly lower in C3 glomerulopathy patients compared to controls (P<0.001), with concurrent elevation of C3 breakdown products (C3d, Bb) indicating active cleavage. 6
Factor B consumption parallels C3 depletion because Factor B is the enzymatic component of the alternative pathway C3 convertase; Factor B levels are significantly suppressed in both dense deposit disease and C3 glomerulonephritis (P<0.001 for both). 6
Normal C4 levels distinguish alternative pathway activation from classical pathway activation, because C4 is not involved in the alternative pathway; isolated low C3 with normal C4 is the hallmark laboratory pattern. 1, 3
Temporal Sequence in Post-Infectious Glomerulonephritis
Post-streptococcal glomerulonephritis demonstrates the temporal relationship between complement activation and clinical disease:
Pre-clinical complement activation occurs before nephritis symptoms appear; properdin levels drop and C3 splitting activity becomes detectable 1-2 days before gross hematuria develops. 5
Acute phase consumption produces profound depression of C3, properdin, and C5 levels once clinical nephritis manifests, reflecting maximal alternative pathway activation in glomeruli. 5
Recovery within 8-12 weeks is expected in uncomplicated post-infectious cases; persistent low C3 beyond 12 weeks indicates primary C3 glomerulopathy rather than infection-triggered disease and mandates kidney biopsy with comprehensive complement work-up. 1, 3
Heterogeneity of Complement Abnormalities
Alternative pathway dysregulation in C3 glomerulopathy arises from diverse mechanisms:
Acquired abnormalities predominate in adults, with C3 nephritic factor (an IgG autoantibody that stabilizes C3 convertase) being the most common acquired defect; C3 nephritic factor activity is qualitatively higher in dense deposit disease compared to C3 glomerulonephritis. 2, 6
Genetic risk factors include the H402 and V62 alleles of Factor H (the most common genetic findings), as well as pathogenic mutations in CFH, CFI, and CFHR genes that impair complement regulation. 2
Combined genetic and acquired defects frequently coexist; approximately 30% of C3 glomerulopathy patients with a monoclonal gammopathy have a monoclonal protein that functions as a C3 nephritic factor or anti-Factor H antibody, creating an MGRS-associated disease. 3
Critical Diagnostic Pitfall
C3-dominant immunofluorescence does not always indicate primary C3 glomerulopathy; infection-related glomerulonephritis and masked monoclonal deposits produce identical patterns but require fundamentally different treatments (antimicrobials versus clone-directed therapy versus immunosuppression). 1, 3
Infection screening (hepatitis B, hepatitis C, HIV, endocarditis) must be completed before diagnosing primary C3 glomerulopathy because infections trigger complement abnormalities in genetically susceptible patients. 3
Pronase-digestion immunofluorescence on paraffin-embedded tissue is mandatory when a monoclonal protein is detected, as 5-10% of apparent C3 glomerulopathy cases are actually membranoproliferative glomerulonephritis with hidden monoclonal deposits. 3
Prognostic Implications
Progressive renal dysfunction occurs in the majority of untreated C3 glomerulopathy cases; a ≥40% decline in estimated glomerular filtration rate over 2-3 years predicts poor renal outcome. 3
Post-transplant recurrence develops in C3 glomerulopathy within 1 year of kidney transplantation and causes allograft dysfunction, because the systemic complement dysregulation persists and attacks the new kidney. 2